Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07069712 · ClinicalTrials.gov registry record · Phase 2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
A Phase 2 study of Gastroesophageal Adenocarcinoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT07069712: Recruiting Phase 2 study of Gastroesophageal Adenocarcinoma, sponsored by AstraZeneca.
NCT07069712 is a Phase 2 study of Gastroesophageal Adenocarcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 100 participants, below the 138-participant average among 8 other Gastroesophageal Adenocarcinoma trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07069712, a Phase 2 study of Gastroesophageal Adenocarcinoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.
Primary Outcome
To assess the safety and tolerability of perioperative treatment.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG 5-Fluorouracil (5-FU)
- DRUG Rilvegostomig
- DRUG AZD0901
- DRUG Trastuzumab Deruxtecan (T-DXd)
Study Locations (20)
Other
- Research Site - Beijing
- Research Site - Changchun
- Research Site - Changzhi
- Research Site - Chengdu
- Research Site - Chengdu
- Research Site - Fuzhou
- Research Site - Hangzhou
- Research Site - Hangzhou
- Research Site - Kunming
- Research Site - Qingdao
New York
- Research Site - New York
- Research Site - New York
Quebec
- Research Site - Montreal
- Research Site - Montreal
Delaware
- Research Site - Newark
District of Columbia
- Research Site - Washington D.C.
Kansas
- Research Site - Fairway
Michigan
- Research Site - North Shores
Pennsylvania
- Research Site - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-07-17 |
| Est. Completion | 2028-09-06 |
| Phase | Phase 2 |
What NCT07069712 shows while recruiting
NCT07069712 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 138-participant average among 8 other Gastroesophageal Adenocarcinoma trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Gastroesophageal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT07069712 names 20 study sites across 9 states, led by Other, New York, Quebec.
Frequently Asked Questions
What is clinical trial NCT07069712 about?
NCT07069712 is a clinical study titled "A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma". GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcin...
What is the current status of trial NCT07069712?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-07-17. Estimated completion is 2028-09-06.
What conditions does trial NCT07069712 study?
This clinical trial studies the following conditions: Gastroesophageal Adenocarcinoma.
What interventions are being tested in trial NCT07069712?
The interventions under investigation include: Capecitabine (DRUG), 5-Fluorouracil (5-FU) (DRUG), Rilvegostomig (DRUG), AZD0901 (DRUG), Trastuzumab Deruxtecan (T-DXd) (DRUG).
Who is sponsoring clinical trial NCT07069712?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07069712 being conducted?
This trial has 20 study locations across Delaware, District of Columbia, Kansas, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07069712's enrollment target sits among peer trials
100 4th of 8 higher than 5 of 8 other Gastroesophageal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
RECRUITING · Phase 2
-
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
ACTIVE NOT RECRUITING · Phase 2
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
RECRUITING · Phase 1
-
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
RECRUITING · Phase 1
-
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI